1. <button id="lxmwl"></button>

        <tbody id="lxmwl"><track id="lxmwl"></track></tbody>
        1. <progress id="lxmwl"></progress>
        2. <dd id="lxmwl"></dd>
        3. 歡迎來到振東健康網  
          網站首頁 男性健康 女性健康 育兒保健 老年健康 健康自測 查藥品 查疾病 健康資訊

          健康資訊

        4. 首頁 > 
        5. 健康資訊 > 
        6. 學術前沿 > 
        7. 《細胞》子刊:新的診斷分析方法能為肺癌患者制定個性化治療方案

          發布時間:2021年08月31日 08:16:11 來源:振東健康網

          《細胞》子刊:新的診斷分析方法能為肺癌患者制定個性化治療方案

          資訊作者:University of Helsinki

          編輯翻譯:奇奇


          本文獻于2021年8月18日發表在國際著名期刊《細胞報告醫學》(Cell Reports Medicine)上。文中赫爾辛基大學的研究人員發現一種新的診斷分析方法,這種方法能為肺癌患者提供個性化治療方案,也為其他癌癥治療方案提供了新思路。

          赫爾辛基大學的一項新研究表明,從肺癌中新分離出來的細胞可以用來建立可靠的藥物反應數據。這種方法可以識別可操作的或無反應的治療,案例說明中該分析用于指導對患者的治療。

          每種癌癥組織都是獨特的,這讓治療策略復雜化。因此,精準醫療在將治療方法與患者個體相匹配方面的力量是顯而易見的。然而,它在臨床上的實際成功仍然有限,特別是對于實體腫瘤。

          肺癌是世界上最常見的癌癥,與其他癌癥類型相比其預后較差。根據基因突變分析,大約三分之一的非小細胞肺癌患者可以找到匹配的治療方法,但只有略多于一半的患者受益于這種基因匹配治療。其中一個問題是缺乏診斷上可解釋的檢測方法,這種方法可以為特定癌癥確定最有希望的治療方法。

          為了克服這一挑戰,由來自赫爾辛基大學芬蘭分子醫學研究所的Emmy Verschuren領導的研究小組驗證了一種檢測方法,可以在術后立即對肺癌樣本進行藥物反應測量。他們將這種潛在方法的研究結果發表在了《細胞報告醫學》雜志上。

          對于血液系統惡性腫瘤患者來說,FIMM精準癌癥藥物的作用以及協同團隊通過分析來自患者的血液樣本的分析方法,在為患者匹配個性化治療方面取得了巨大進展。然而,對于實體上皮腫瘤,卻不能簡單地采用這些方法。

          Emmy博士認為,現在仍然非常需要強大的診斷細胞模型。這是因為現有的診斷細胞模型建立的時間較長,重要的是,還不能保證惡性細胞的擴增。

          Emmy博士說:“為了解是否可以利用腫瘤組織獲得可靠的數據,我們已經進行了多年的研究。我們發現腫瘤組織極其脆弱,手術后隨著時間的推移,其生物學變化越來越明顯。這一點也毫不奇怪?!?/span>

          在他們最近與哥本哈根大學的Krister Wennerberg教授合作的概念驗證研究中,她的團隊旨在開發一種替代方法來規避這些挑戰。該團隊開始評估未培養的腫瘤細胞群是否可以在分離后立即用于藥物分析。研究結果證明了研究人員所謂的新鮮未培養的腫瘤細胞(FUTCs)的效用。

          該團隊通過分析20個非小細胞肺癌患者的樣本來檢測該方法。所用藥物篩選小組包含了66種肺癌選擇性藥物。他們的檢測結果表明,在20例患者中有19例產生了可靠的藥物反應數據。遺傳癌癥突變分析和藥物敏感性數據很好地匹配,為該方法的有效性提供了進一步的支持。

          根據患者的要求,通過對難治性轉移性非小細胞肺癌患者的治療和現實世界的轉化,證實了基于FUTC的功能性方法的前景。根據篩選結果選擇三種藥物進行治療,患者從中獲得了臨床益處。

          該研究的第一作者、來自FIMM的Sarang Talwelkar說:“FUTC檢測方法能夠在樣本收集后72小時左右對癌細胞進行藥理學測試,從而以一種個性化的方式影響臨床治療決策?!被贔UTC的診斷還有助于預測臨床對高價靶向治療的無反應,以降低其可觀的成本。

          Emmy博士說:“雖然現在還處于早期階段,需要進一步在活檢中檢測FUTC分析,但我們希望我們的檢測能夠越來越多地讓復發性肺癌患者受益?!盬ennerberg教授補充道:“此外,通過更廣泛地適應其他癌癥類型的方法,我們可以了解到什么,這也將變得很有意義?!?/span>


          英語原文

          New Diagnostic Assay Holds Potential for Tailoring Personalized Cancer Treatment

          A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.

          Each cancer tissue is unique, complicating treatment decisions. The power of precision medicine to match treatments to and individual patient is therefore evident. Yet, its actual success in the clinichas remained limited, particularly for solid tumors.

          Lung cancer is the most common cancer worldwide and has a poor prognosis compared to other cancer types. Based on genetic mutation analyses, matched treatments can be identified for around a third of patients with non-small cell lung cancer, but only just over half of all patients benefit from such gene-matched treatments. One of the issues is the lack of diagnostically interpretable assays that can identify the most promising treatment for a particular cancer.

          To overcome this challenge, a research team led by Emmy Verschuren from the Institute for Molecular Medicine Finland FIMM, University of Helsinki, validated an assay to enable drug response measurements in lung cancer samples immediately following surgery. Their promising approachhas just been published in the journal Cell Reports Medicine.

          For patients with hematological malignancies, the FIMM precision cancer medicine efforts and collaborating teams have made great progress on matching individualized therapies to patients via the analysis of patient-derived blood samples. However, for solid epithelial tumors, these methods cannot simply be adopted.

          According to Dr. Verschuren, there still is a great need for robust diagnostic cell models since the presently available models take long times to be established, and importantly, do not guarantee the expansion of malignant cells.

          “We have invested many years ofresearch to understand whether tumor tissue can be used to obtain reliable data. Not surprisingly, we learned that tissue is extremely fragile, and biological changes are increasingly pronounced with time elapsed since thesurgery,” says Dr. Emmy Verschuren.

          In their recent proof-of-concept study in collaboration with Professor Krister Wennerberg from the University of Copenhagen, her group aimed to develop an alternative approach to circumvent these challenges. The team set out to assess whether uncultured tumor cell populations could be used for drug profiling, immediately following their isolation. The research findings demonstrate the utility of what the researchers called Fresh Uncultured Tumor Cells, or FUTCs.

          The team tested the method by profiling twenty non-small cell lung cancer patient samples. The drug screening panelused contained 66 lung cancer-selective drugs.

          Their results demonstrated that robust drug response data was generated in 19 of 20 patient cases. Genetic cancer mutation analyses and the drug sensitivity data were well aligned, providing further support for the validity of the approach.

          The promise of FUTC-based functional approach was also demonstrated via real-world translation, through compassionate treatment of a patient with refractory metastatic non-small celllung cancer, per the patient's request. The patient received clinical benefit from the treatment with three drugs selected based on the screening results.

          “The FUTC assay enables pharmacological testing of cancer cells in around 72 hours after sample collection and thus offers a possibility to impact treatment decision in the clinic, in anindividualized manner,” says the first author of the study, Sarang Talwelkar from FIMM. FUTC-based diagnostics could additionally help to predict clinical non-responses to highly-priced targeted therapies to decrease their considerable costs.

          “While it remains early days, and further investigation is warranted to test FUTC profiling on biopsies, we are hopeful that our assay can increasingly benefit patients with recurrent lung cancer,” says Dr. Verschuren. “In addition, it will be intriguing to see what we may learn by broader adaptation of the approach to other cancer types,” adds Prof. Wennerberg.


          參考文獻

          Sarang S. Talwelkar et al, Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments, Cell Reports Medicine (2021). DOI: 10.1016/j.xcrm.2021.100373


          本文內容由振東健康網整理發布

          0
          加入收藏
          熱門排行榜
          国产亚洲精品免费观看视频,97bb,国产精品国产自线拍,965影视网站,国偷自产第107页 国家宝藏2高清下载| 一本大道高清在线视频| 爱情的限度迅雷下载| 久久电影网| 在线观看精品国产福利片| 碟中谍2迅雷下载| 日本高清免费中文字幕专区| 欧美三级电影| 上别人丰满人妻| 金梅瓶2| 欧美高清videossexohd| 黄网站有哪些| 芭乐app| 国偷自产第107页| 爱情岛论坛免费网站线路一| 屁屁影院| 爱的色放在线看| 一日本道伊人久久综合影| 女人的比比| 国产在线观看| 日韩精品无码免费专区| 250pp情艺中心| 色域网| 欧美海军聚会图片| 在线电影欧美日韩国产| 久久人人97超碰人人澡| 午夜奸魔| 中文字幕亚洲无线码一区| 聊斋志异孽欲狐仙| 九州av| 碟中谍2迅雷下载| 爱情公寓5免费播放| 爱的色放完整版在线| 国产精品自在在线午夜蜜芽tv在线| 在线看免费观看日本AV动态| 2013年9月里番| 情感口述小说| 在线观看密爱| 在线视频无码美脚丝袜| 抖阴app| 日照天劫| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>